TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.160nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.180nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.180nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.260nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.320nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.380nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.390nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.440nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 0.780nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: 2nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.10nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 2.40nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of GCN2 (unknown origin)More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 3.40nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetUbiquitin carboxyl-terminal hydrolase 7(Homo sapiens (Human))
Rapt Therapeutics
Curated by ChEMBL
Rapt Therapeutics
Curated by ChEMBL
Affinity DataIC50: 4.60nMAssay Description:Inhibition of recombinant full length USP7 (unknown origin) using ubiquintin-rhodamine as substrate preincubated for 30 mins followed by substrate ad...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair
TargetcAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A(Homo sapiens (Human))
Mochida Pharmaceutical
US Patent
Mochida Pharmaceutical
US Patent
Affinity DataIC50: <5nMAssay Description:IMAP TR-FRET Phosphodiersterase Evaluation Assay Kit (Molecular Device) was used for the measurement. Ten μL of a diluted test compound having e...More data for this Ligand-Target Pair